 |
|
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Douglas E. Gladstone, MD;
Kenneth W. Zamkoff, MD;
Lauren Krupp, MD;
Robert Peyster, MD;
Patrick Sibony, MD;
Christopher Christodoulou, PhD;
Emily Locher, RN;
Patricia K. Coyle, MD
Arch Neurol. 2006;63:(doi:10.1001/archneur.63.10.noc60076).
Background High-dose cyclophosphamide is active in immune-mediated illnesses.
Objective To describe the effects of high-dose cyclophosphamide on severe refractory multiple sclerosis.
Design, Setting, and Patients Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) score of 3.5 or higher after 2 or more Food and Drug Administration–approved disease-modifying therapy regimens were evaluated.
Interventions Patients received 200 mg/kg of cyclophosphamide over 4 days.
Main Outcome Measures Patients had brain magnetic resonance imaging and neuro-ophthalmologic evaluations every 6 months and quarterly EDSS and quality-of-life evaluations for 2 years.
Results Twelve patients were evaluated for clinical response (median follow-up, 15.0 months; follow-up range, 6-24 months). During follow-up, no patients increased their baseline EDSS scores by more than 1.0. Five patients decreased their EDSS scores by 1.0 or more (EDSS score decrease range, 1.0-5.0). No patient had a new lesion on brain magnetic resonance imaging. No patient showed any enhancing lesions. Patients reported improvement in all of the quality-of-life parameters measured. Neurologic improvement involved changes in gait, bladder control, and visual function. Treatment response was seen regardless of the baseline presence or absence of contrast lesion activity. Patient quality-of-life improvement occurred independently of EDSS score changes. In this small group of patients with treatment-refractory multiple sclerosis, high-dose cyclophosphamide was associated with minimal morbidity and improved clinical outcomes.
Conclusions High-dose cyclophosphamide treatment in patients with severe refractory multiple sclerosis can result in disease stabilization, improved functionality, and improved quality of life. Further studies are necessary to determine the most appropriate patients for this treatment.
Published online August 14, 2006 (doi:10.1001/archneur.63.10.noc60076).
Author Affiliations: Departments of Medicine (Drs Gladstone and Zamkoff and Ms Locher), Neurology (Drs Krupp, Christodoulou, and Coyle), Radiology (Dr Peyster), and Ophthalmology (Dr Sibony), State University of New York at Stony Brook.
|
